Effects of Exenatide plus Metformin versus Metformin alone on insulin resistance in women with Polycystic Ovary Syndrome: A systematic review and meta‐analysis
Journal of Obstetrics and Gynaecology Research · 2025-05 · 51 (5)
DOI: 10.1111/jog.16296 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Obstetrics and Gynaecology Research, online erschienen am 29.04.2025. Verfasst von Abd-Alrahman Al-Qudah und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Jordan, Amman, Jordan. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Metformin, Insulin Resistance, Exenatide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
Polycystic ovary syndrome (PCOS) is a common endocrine disorder among reproductive‐age women, often accompanied by insulin resistance, obesity, and increased metabolic risk. While Metformin (MET) is commonly used to improve insulin sensitivity, its limited effect on postprandial glucose has led to interest in combination therapies. Exenatide (EX), a glucagon‐like peptide‐1 receptor agonist, may offer complementary benefits.
Objective
To assess the effectiveness of EX combined with MET (EX + MET) versus MET alone (MET) in improving insulin resistance and metabolic outcomes in overweight and obese women with PCOS.
Methods
This systematic review and meta‐analysis included five randomized controlled trials ( n = 339) and followed Preferred Reporting Items for Systematic reviews and Meta‐Analysis Extension guidelines. The primary outcome was the change in insulin resistance (Homeostatic Model Assessment of Insulin Resistance [HOMA‐IR]). Secondary outcomes included body mass index (BMI), 2‐h oral glucose tolerance test (OGTT), lipid profile, and reproductive hormones.
Results
Pooled analysis revealed that EX + MET significantly reduced HOMA‐IR (mean difference [MD]: –0.9; p < 0.001), improved 2‐h OGTT values (MD: –1.78; p < 0.001), reduced BMI (MD: –0.4; p = 0.03), with low heterogeneity. Combination therapy also improved triglyceride and total cholesterol levels. However, no significant effects were observed on reproductive hormones or low‐density lipoprotein and high‐density lipoprotein cholesterol.
Conclusions
While hormonal and some lipid changes were not significant, their inclusion highlights the multifaceted impact of PCOS and the need for longer‐term studies. By improving insulin sensitivity and weight‐related outcomes, EX + MET may be a valuable clinical option for metabolically high‐risk PCOS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Jordan, Amman, Jordan.
- Jordanian Royal Medical Services, Amman, Jordan.
ORCID-Profile: Abd-Alrahman Al-Qudah
Zitieren
APA
Al-Qudah, A. A., Al-Hanaktah, M., & Albadaineh, R. (2025). Effects of Exenatide plus Metformin versus Metformin alone on insulin resistance in women with Polycystic Ovary Syndrome: A systematic review and meta‐analysis. Journal of Obstetrics and Gynaecology Research, 51(5). https://doi.org/10.1111/jog.16296
Vancouver
Al-Qudah AA, Al-Hanaktah M, Albadaineh R. Effects of Exenatide plus Metformin versus Metformin alone on insulin resistance in women with Polycystic Ovary Syndrome: A systematic review and meta‐analysis. Journal of Obstetrics and Gynaecology Research. 2025;51(5). doi:10.1111/jog.16296
BibTeX
@article{AlQudah2025,
author = {Al-Qudah, Abd-Alrahman and Al-Hanaktah, Mohammad and Albadaineh, Reham},
title = {Effects of Exenatide plus Metformin versus Metformin alone on insulin resistance in women with Polycystic Ovary Syndrome: A systematic review and meta‐analysis},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2025},
volume = {51},
number = {5},
doi = {10.1111/jog.16296}
}
EUVIMED